NeoGenomics, Inc. — FY 2015 Form 10-K
Reporting period: Fiscal year ended December 31, 2015. The filing is an annual report, not a standalone Q4 filing; quarterly figures are noted where relevant. NeoGenomics operates cancer-focused genetic and molecular testing laboratories. Clarient was acquired on December 30, 2015, so its operating results contributed only two days to reported FY 2015 results.
Financial performance and position
| Metric | FY 2015 | FY 2014 |
|---|---|---|
| Revenue | $99.8 million | $87.1 million |
| Gross profit / margin | $43.8 million / 43.8% | $40.7 million / 46.8% |
| Operating income (loss) | ($5.6) million | $2.2 million |
| Net income (loss) | ($2.5) million | $1.1 million |
| Net income (loss) per diluted share | ($0.04) | $0.02 |
| Cash from operations | $6.4 million | $9.5 million |
| Adjusted EBITDA (non-GAAP) | $9.7 million; 9.7% of revenue | $9.2 million; 10.5% of revenue |
Testing requisitions increased 34.3% to 204,282; reported revenue rose 14.6%. Average revenue per requisition fell 14.7% to $489, primarily reflecting 2015 CMS reimbursement reductions for FISH testing. Cost per requisition declined 10%, but gross margin contracted by 3.0 percentage points. Management attributed the GAAP loss mainly to acquisition-related costs and lower FISH reimbursement; 2015 also included a one-time $2.0 million gain from a contract amendment.
At year-end, cash was $23.4 million, working capital was $59.0 million, and total assets were $368.0 million. Reported debt included $8.9 million outstanding on the revolver and $52.8 million net term-loan debt, in addition to capital leases and other borrowings. The revolver had approximately $15 million available. Cash declined from $33.7 million at year-end 2014. Investing cash outflow was $75.2 million, largely reflecting the Clarient acquisition.
Material changes and acquisition
- Clarient was acquired for approximately $249.5 million in cash, common stock and Series A preferred stock. The transaction added $15 million common shares and 14.7 million preferred shares; GE’s ownership was approximately 32% on a fully diluted basis.
- Acquisition financing included a $55 million term loan and $10 million revolver borrowing. The preferred stock has a $110 million initial liquidation value and cumulative, increasing PIK dividends; the filing estimates a $190.8 million liquidation value after ten years if not redeemed or converted.
- Clarient contributed $665,000 revenue and $26,000 net income for the two days included in reported results. Preliminary purchase accounting recorded $143.5 million goodwill and $84 million intangible assets; measurements remained subject to change.
- Unaudited pro forma results assuming Clarient had been included since January 1, 2014 show revenue of $216.0 million in 2015 and $214.3 million in 2014, but losses attributable to common stockholders of $71.4 million and $34.1 million, respectively. These illustrative figures are not reported historical results.
Outlook, commentary and risks
- Management expected the combined company to more than double in size in 2016, improve profitability each quarter as integration progressed, and achieve at least $6 million of cost synergies in 2016, with further synergies afterward. These are expectations, not guarantees.
- Integration priorities included a unified test menu, laboratory information and billing systems, retaining clients, and consolidating facilities. Management planned $12–$16 million of 2016 capital expenditures.
- Management said CMS’s 2016 FISH technical-component rates increased 69%–96%, which it expected to stabilize or improve revenue per test. Reimbursement policy, payer coverage, collection timing, and Medicare payment changes remain significant uncertainties.
- Debt agreements impose leverage and fixed-charge coverage covenants beginning in Q1 2016; the term loan and revolver carry variable rates. The company also faces preferred-stock redemption and dilution provisions, including use of at least 50% of certain future cash financing proceeds to redeem preferred shares.
- Other material risks include successfully integrating Clarient and realizing synergies, maintaining quality and client relationships, reimbursement and billing compliance, potential FDA oversight of laboratory-developed tests, competition and pricing pressure, and scaling operations and IT systems.
- Management and the auditor reported effective internal controls for the assessment performed, but Clarient was excluded from the control assessment and audit scope; Clarient represented 76% of consolidated assets and 1% of 2015 revenue.
Most important facts for investors to verify
- Whether Clarient integration delivers the stated $6 million or more in synergies, improves quarterly profitability, and retains clients.
- Actual post-acquisition revenue, margins, cash conversion and adjusted EBITDA, compared with the unaudited pro forma losses and management’s outlook.
- FISH and other test reimbursement changes, payer coverage, receivables aging and collections; 19% of gross receivables were over 120 days at year-end.
- Debt covenant headroom, variable-rate exposure, scheduled repayments, and the economic impact of preferred-stock dividends, redemption terms and potential dilution.
- Final purchase-price allocation and goodwill/intangible valuations, plus progress bringing Clarient within the company’s internal-control framework.